Clinical trials: Cell Transplantation
Veno-occlusive Disease
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
RATIONALE: Giving defibrotide may be an effective treatment for liver damage that may result following peripheral stem cell transplantation.
- Trial name
- NCT00003966
- Testing
- defibrotide
- Where
- 9 sites in United States
- Volunteers
- 151 people
- Sponsor
- Dana-Farber Cancer Institute
Thalassemia Major
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.
- Trial name
- NCT03171831
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Stroke
Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
The purpose of this study is to evaluate the safety and efficacy of autologous peripheral hematopoietic stem cell transplantation in ischemic stroke.
- Trial name
- AHSCTIS (NCT01518231)
- Testing
- autologous hematopoiesis stem cell transplantation, Aspirin, Warfarin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Hospital
Lymphoma, Leukemia
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of…
- Trial name
- NCT00048737
- Testing
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or haploidentical stem cell transplant.
- Trial name
- NCT02169505
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Spinal Cord Injuries
Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training
Umbilical cord blood mononuclear stem cells (UCBMSCs) transplant followed by the intensive locomotor training for up to 5±1 hours a day, 5±1 days a week, and for 3-6 months for treatment in patients with chronic, stable and…
- Trial name
- NCT03979742
- Testing
- Umbilical Cord Blood Mononuclear Cell, Locomotor Training
- Where
- 2 sites in Taiwan
- Volunteers
- 6 people
- Sponsor
- StemCyte, Inc.
Multiple Myeloma
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1) or only 2 x 4 days of dexamethasone (A2).
- Trial name
- DSMM-II (NCT02288741)
- Testing
- Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization
- Volunteers
- 549 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Viral Infection
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell…
- Trial name
- TETRAVI (NCT04013802)
- Testing
- HLA-matched VSTs
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Multiple Myeloma
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma (MM). Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of…
- Trial name
- NCT00934154
- Testing
- Thalidomide, Melphalan+Prednisolone
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Cigdem Sahinbas YILMAZ
DLBCL - Diffuse Large B Cell Lymphoma
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient…
- Trial name
- NCT06299553
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Incyte Biosciences Italy S.r.l
Non-Hodgkins Lymphoma
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.
- Trial name
- NCT00856245
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Myeloma Multiple
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma…
- Trial name
- NCT06245629
- Testing
- Bortezomib-bendamustine-melphalan
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Uppsala University
Myelodysplastic Syndromes, Myeloid Leukemia, Acute
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in…
- Trial name
- TMLI-MA (NCT06598969)
- Testing
- Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Graft Versus Host Disease
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
This phase I trial studies the side effects and best dose of donor regulatory T cells in treating patients with graft-versus-host disease affecting the liver or gastrointestinal organs (visceral) within 100 days (acute) after…
- Trial name
- NCT02526329
- Testing
- donor regulatory T lymphocytes, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Everett Meyer
Multiple Myeloma
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of…
- Trial name
- NCT03896737
- Testing
- Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
- Where
- 24 sites in Czechia, Greece and 1 more
- Volunteers
- 401 people
- Sponsor
- European Myeloma Network B.V.
Solid Malignancies
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
Hypothesis : pegfilgrastim at 200 µg/kg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study.
- Trial name
- MEG-5 (NCT00751894)
- Testing
- Pegfilgrastim (Neulasta, Amgen)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Anemia, Sickle Cell
Siplizumab for Sickle Cell Disease Transplant
The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure.
- Trial name
- CD2 SCD (NCT06078696)
- Testing
- Siplizumab, Exchange Transfusion, Total Body Irradiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Hematopoietic Cell Transplantation, Oncology
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the only curative treatment modality for many hematologic malignancies. Morbidity and mortality rates have declined drastically over the years, secondary to improvements in both…
- Trial name
- IMPPACT (NCT04727827)
- Testing
- Pharmacogenomic-guided supportive care
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
New Onset Diabetes Mellitus After Renal Transplantation
Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation
New onset diabetes after transplantation (NODAT) is a frequent and feared complication after kidney transplantation and leads to an increase in cardiovascular complications as well as in the rate of graft loss.
- Trial name
- ISINODAT (NCT01268995)
- Testing
- Cyclosporine A, Tacrolimus
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
Diffuse Large B Cell Lymphoma
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
To evaluate the efficacy and safety of selinexor combined with BEAM pretreatment regimen in ASCT of recurrent and refractory DLBCL patients with immunohistochemical positive for MYC
- Trial name
- NCT06652139
- Testing
- selinexor combined with BEAM regimen, BEAM regimen
- Volunteers
- 82 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.